Physician profile
Russ Bodner
NPI 1639149693
$6,438.80
in general payments reported to CMS, 2019-2025
15 companies · $14.03 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,365 · 2021: $2,581 · 2022: $145 · 2023: $315 · 2024: $18.44 · 2025: $14.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,680.00 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $2,266.10 | 2020-2021 | |
| Abbvie INC. | $112.77 | 2022-2024 | Ubrelvy, Qulipta |
| Pfizer INC. | $72.13 | 2023-2025 | |
| Celgene Corporation | $62.65 | 2023 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $47.01 | 2023 | Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.71 | 2022 | |
| Merz Pharmaceuticals, LLC | $32.00 | 2023 | Xeomin |
| Grifols USA, LLC | $24.11 | 2022 | |
| Biogen, INC. | $22.44 | 2023 | Vumerity |
| Neurocrine Biosciences, INC. | $17.12 | 2022 | |
| Tg Therapeutics, INC. | $15.47 | 2023 | |
| Argenx US, INC. | $14.14 | 2022 | |
| Lilly USA, LLC | $13.26 | 2023 | Amyvid |
| Novartis Pharmaceuticals Corporation | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russ Bodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.